Targacept Shows Positive Results For Phase 2b Clinical Trial Of TC-5214

Targacept has showed positive top-line results from a double blind, placebo controlled, flexible dose phase 2b clinical trial of TC-5214. It is to be used as an augmentation treatment for major depressive disorder (MDD) in subjects who did not respond adequately to first-line treatment with citalopram alone.

Geoffrey Dunbar, vice president, Clinical Development and Regulatory Affairs at Targacept, said: “The strong results from this Phase 2b augmentation trial support the potential of TC-5214 to provide much needed help for the millions of depressed patients who do not respond adequately to currently available therapies.”

“This is the second time our clinical trials have shown antidepressant effects of this NNR mechanism. We are particularly enthusiastic about the finding in this study on irritability, which is a core symptom of MDD that is often difficult to treat,” he added.